Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients

Pediatric Blood and Cancer

Volumn 59, Issue 1, 2012, Pages 144-148

  Yancey, Allison ^a   Harris, Michael S ^b   Egbelakin, Akinbode ^a   Gilbert, Jaimie ^b   Pisoni, David B ^b   Renbarger, Jamie ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Cisplatin; Hearing loss; Ototoxicity; Risk factors

Indexed keywords

CISPLATIN;

AGE; ARTICLE; AUDIOGRAPHY; BROCK SCALE; CANCER DIAGNOSIS; CHILD; CHILDHOOD CANCER; CHILDHOOD DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE; DRUG INDUCED DISEASE; FEMALE; GERM CELL TUMOR; HEARING LOSS; HEPATOBLASTOMA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROBLASTOMA; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CISPLATIN; FOLLOW-UP STUDIES; HEARING LOSS; HUMANS; INFANT; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84861205340     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24138     Document Type: Article

References (18)

1. Coradini PP, Cigana L, Selistre SG, et al. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol 2007; 29: 355-360.
2. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649-655.
3. Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107: 417-422.
4. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23: 8588-8596.
5. Gurney JG, Tersak JM, Ness KK, et al. Children's Oncology Group. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children's Oncology Group. Pediatrics 2007; 120: e1229-e1236.
6. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer 2004; 40: 2445-2451.
7. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 1991; 19: 295-300.
8. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010; 28: 1788-1795.
9. Ross CJ, Katzov-Eckert H, Dube MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41: 1345-1349.
10. Lewis MJ, DuBois SG, Fligor B, et al. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 2009; 52: 387-391.
11. Zuur CL, Simis YJ, Lansdaal PE, et al. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer. Audiol Neurootol 2006; 11: 318-330. Epub 2006 Sep 18.
12. Huang RS, Kistner EO, Bleibel WK, et al. Effects of population and gender on chemotherapeutic agent-induced cytotoxicity. Mil Cancer Ther 2007; 6: 31-36.
13. Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000; 11: 639-643.
14. Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 1998; 22: 669-674.
15. Dean JB, Hayashi SS, Albert CM, et al. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol 2008; 30: 130-134.
16. Neuwelt EA, Brock P. Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 2010; 28: 1630-1632.
17. Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25: 708-714.
18. Caronia D, Patino-Garcia A, Milne RL, et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy, clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009; 9: 347-353.